Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2023 Dec 31;12(12):3227-3232.
doi: 10.21037/tcr-23-1629. Epub 2023 Nov 13.

KRAS G12C inhibitors: also a new promising new targeted therapy in advanced pancreatic adenocarcinoma?

Marie Muller  1 , David Tougeron  2
Affiliations
Editorial

KRAS G12C inhibitors: also a new promising new targeted therapy in advanced pancreatic adenocarcinoma?

Marie Muller et al. Transl Cancer Res. .
No abstract available

Keywords: KRAS G12C; adagrasib; cancer; sotorasib; targeted therapy.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at https://tcr.amegroups.com/article/view/10.21037/tcr-23-1629/coif). D.T. reports he receiving consulting or advisory board fees from Amgen. The other author has no conflicts of interest to declare.

Comment on

  • Sotorasib in KRAS p.G12C-Mutated Advanced Pancreatic Cancer.
    Strickler JH, Satake H, George TJ, Yaeger R, Hollebecque A, Garrido-Laguna I, Schuler M, Burns TF, Coveler AL, Falchook GS, Vincent M, Sunakawa Y, Dahan L, Bajor D, Rha SY, Lemech C, Juric D, Rehn M, Ngarmchamnanrith G, Jafarinasabian P, Tran Q, Hong DS. Strickler JH, et al. N Engl J Med. 2023 Jan 5;388(1):33-43. doi: 10.1056/NEJMoa2208470. Epub 2022 Dec 21. N Engl J Med. 2023. PMID: 36546651 Free PMC article. Clinical Trial.

References

    1. Lee YT, Tan YJ, Oon CE. Molecular targeted therapy: Treating cancer with specificity. Eur J Pharmacol 2018;834:188-96. 10.1016/j.ejphar.2018.07.034 - DOI - PubMed
    1. Hobbs GA, Der CJ, Rossman KL. RAS isoforms and mutations in cancer at a glance. J Cell Sci 2016;129:1287-92. 10.1242/jcs.182873 - DOI - PMC - PubMed
    1. Moore AR, Rosenberg SC, McCormick F, et al. RAS-targeted therapies: is the undruggable drugged? Nat Rev Drug Discov 2020;19:533-52. 10.1038/s41573-020-0068-6 - DOI - PMC - PubMed
    1. van de Haar J, Ma X, Ooft SN, et al. Codon-specific KRAS mutations predict survival benefit of trifluridine/tipiracil in metastatic colorectal cancer. Nat Med 2023;29:605-14. 10.1038/s41591-023-02240-8 - DOI - PMC - PubMed
    1. Ostrem JM, Peters U, Sos ML, et al. K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature 2013;503:548-51. 10.1038/nature12796 - DOI - PMC - PubMed